Current Oncology is published by MDPI from Volume 28 Issue 1 (2021).
Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence,
and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature
Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(s1), 19-28; https://doi.org/10.3747/co.22.2363
Received: 12 December 2014 / Revised: 13 January 2015 / Accepted: 13 February 2015 / Published: 1 March 2015
Breast tumours positive for HER2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-HER2 therapies has dramatically improved disease control and survival in patients with metastatic HER2-positive breast cancer. Targeted agents are now considered the standard of care in the first-line setting and beyond. The present review summarizes the currently available data on targeted anti-HER2 therapies from completed randomized phase III clinical trials and briefly discusses emerging advances that will address unmet needs in metastatic HER2-positive breast cancer.
Keywords:
her2; metastatic breast cancer; targeted therapy; phase iii trials
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Zhu, X.; Verma, S. Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. Curr. Oncol. 2015, 22, 19-28. https://doi.org/10.3747/co.22.2363
AMA Style
Zhu X, Verma S. Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. Current Oncology. 2015; 22(s1):19-28. https://doi.org/10.3747/co.22.2363
Chicago/Turabian StyleZhu, X.; Verma, S. 2015. "Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature" Curr. Oncol. 22, no. s1: 19-28. https://doi.org/10.3747/co.22.2363
Find Other Styles
